Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 18;11(6):573.
doi: 10.3390/jpm11060573.

Influence of the FCGR2A rs1801274 and FCGR3A rs396991 Polymorphisms on Response to Abatacept in Patients with Rheumatoid Arthritis

Noelia Márquez Pete  1 , María Del Mar Maldonado Montoro  2 , Cristina Pérez Ramírez  1   3 , Fernando Martínez Martínez  4 , Juan Enrique Martínez de la Plata  5 , Abdelali Daddaoua  6 , Alberto Jiménez Morales  1
Affiliations

Influence of the FCGR2A rs1801274 and FCGR3A rs396991 Polymorphisms on Response to Abatacept in Patients with Rheumatoid Arthritis

Noelia Márquez Pete et al. J Pers Med. .

Abstract

Abatacept (ABA) is an immunosuppressant indicated for treatment of rheumatoid arthritis (RA). Effectiveness might be influenced by clinical RA variants and single-nucleotide polymorphisms (SNPs) in genes encoding protein FCGR2A (His131Arg) and FCGR3A (Phe158Val) involved in pharmacokinetics of ABA. An observational cohort study was conducted in 120 RA Caucasian patients treated with ABA for 6 and 12 months. Patients with the FCGR2A rs1801274-AA genotype (FCGR2A-p.131His) showed a better EULAR response (OR = 2.43; 95% CI = 1.01-5.92) at 12 months and low disease activity (LDA) at 6 months (OR = 3.16; 95% CI = 1.19-8.66) and 12 months (OR = 6.62; 95% CI = 1.25-46.89) of treatment with ABA. A tendency was observed towards an association between the FCGR3A rs396991-A allele (FCGR3A-p.158Phe) and better therapeutic response to ABA after 12 months of treatment (p = 0.078). Moreover, we found a significant association between the low-affinity FCGR2A/FCGR3A haplotypes variable and LDA after 12 months of ABA treatment (OR = 1.59; 95% CI = 1.01-2.58). The clinical variables associated with better response to ABA were lower age at starting ABA (OR = 1.06; 95% CI = 1.02-1.11) and greater duration of ABA treatment (OR = 1.02; 95% CI = 1.01-1.04), lower duration of previous biological therapies (OR = 0.99; 95% CI = 0.98-0.99), non-administration of concomitant disease-modifying antirheumatic drugs (DMARDs) (OR = 24.53; 95% CI = 3.46-523.80), non-use of concomitant glucocorticoids (OR = 0.12; 95% CI = 0.02-0.47), monotherapy (OR = 19.22; 95% CI = 2.05-343.00), lower initial patient's visual analogue scale (PVAS) value (OR = 0.95; 95% CI = 0.92-0.97), and lower baseline ESR (OR = 0.92; 95% CI = 0.87-0.97). This study showed that high-affinity FCGR2A-p.131His variant, low-affinity FCGR3A-p.158Phe variant, and combined use of FCGR2A/FCGR3A genetic variations could affect ABA effectiveness. Further studies will be required to confirm these results.

Keywords: FCGR2A; FCGR3A; abatacept; effectiveness; polymorphisms; rheumatoid arthritis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported, and that there are no competing financial interests in relation to the work described in this article.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Blair H.A., Deeks E.D. Abatacept: A Review in Rheumatoid Arthritis. Drugs. 2017;77:1221–1233. doi: 10.1007/s40265-017-0775-4. - DOI - PubMed
    1. Gazeau P., Alegria G.C., Devauchelle-Pensec V., Jamin C., Lemerle J., Bendaoud B., Brooks W.H., Saraux A., Cornec D., Renaudineau Y. Memory B Cells and Response to Abatacept in Rheumatoid Arthritis. Clin. Rev. Allergy Immunol. 2017;53:166–176. doi: 10.1007/s12016-017-8603-x. - DOI - PubMed
    1. Lobo E.D., Hansen R.J., Balthasar J.P. Antibody Pharmacokinetics and Pharmacodynamics. J. Pharm. Sci. 2004;93:2645–2668. doi: 10.1002/jps.20178. - DOI - PubMed
    1. Montes A., Perez-Pampin E., Joven B., Carreira P., Fernandez-Nebro A., Ordóñez M.D.C., Navarro-Sarabia F., Moreira V., Vasilopoulos Y., Sarafidou T., et al. FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors. Pharmacogenomics. 2015;16:333–345. doi: 10.2217/pgs.14.175. - DOI - PubMed
    1. Tracey D., Klareskog L., Sasso E.H., Salfeld J.G., Tak P.P. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. Pharmacol. Ther. 2008;117:244–279. doi: 10.1016/j.pharmthera.2007.10.001. - DOI - PubMed